Diagonal Bio AB (publ) (DB: 9F1)
Health Care · Biotechnology · SE
€—
— today · — 1Y
Diagonal Bio AB (publ) (DB: 9F1) operates in the Biotechnology industry within the Health Care sector.
trading between 0.00 and 0.00.
Tweenvest scores Diagonal Bio AB (publ) across four factors: quality 30/100. Its strongest factor is quality.
9F1 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $147.83K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- €0.00
- 52-week low
- €0.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 4
- Next earnings
- —
About Diagonal Bio AB (publ)
Diagonal Bio AB operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was founded in 2020 and is headquartered in Lund, Sweden.
- Founded
- 2020
- Listed since
- Jul 16, 2021
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.